Human Albumin Grifols 20% Special Precautions

Human Albumin Grifols 20% is for intravenous administration use.
If allergic reactions occur, the infusion should be stopped immediately. If allergic reactions persist then appropriate treatment is recommended. In anaphylactic reactions, treatment should follow the current recommendations for shock therapy.
The colloid-osmotic effect of human albumin 20% is approximately four times that of blood plasma. Therefore, when concentrated albumin is administered, care must be taken to assure adequate hydration of the patient. Patients should be monitored carefully to guard against circulatory overload and hyperhydration, respectively.
If the required volume of human albumin 20% exceeds 200 ml, appropriate additional electrolyte solutions should be administered to maintain normal fluid balance. Alternatively therapy may be continued with albumin 5%.
If comparatively large volumes are to be replaced, controls of coagulation and haematocrit are necessary. Care must be taken to ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets and erythrocytes). If the haematocrit drops below 30%, packed red cells should be given to maintain the oxygen transport capacity of the blood.
When medicinal products prepared from human blood or plasma are administered, infectious diseases due to the transmission of infective agents cannot be totally excluded. This applies also to pathogens of hitherto unknown nature.
To reduce the risk of transmission of infective agents selection of donors and donations by suitable measures is performed and removal and/or inactivation procedures are included in the production process.
Effects on ability to drive: There are no indications that human albumin may impair the abilities to drive or to operate machines.